NextTrip price target raised to $5 from $2.50 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on NextTrip (NTRP) to $5 from $2.50 and keeps a Neutral rating on the shares after the company ...
Fintel on MSN19h
HC Wainwright & Co. Downgrades Pliant Therapeutics (PLRX)
Fintel reports that on February 10, 2025, HC Wainwright & Co. downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX ...
Corbus Pharmaceuticals (NASDAQ:CRBP) Given Buy Rating at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research ...
H.C. Wainwright maintains Buy on Immunovant, $51 price target
H.C. Wainwright reaffirmed their Buy rating on Immunovant (NASDAQ:IMVT) shares with a price target of $51.00, aligning with the broader Wall Street sentiment. According to InvestingPro data, analyst ...
Oruka Therapeutics’ (ORKA) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright restated their buy rating on shares of Oruka Therapeutics (NASDAQ:ORKA – Free Report) in a report released on ...
Pliant Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Pliant Therapeutics (PLRX) to Neutral from Buy without a price target after the company voluntarily paused ...
H.C. Wainwright & Co. Is Once Again Ranked #1 by PlacementTracker
H.C. Wainwright & Co., LLC, announced its #1 Ranking by transaction volume for the calendar year of 2024, maintaining the Firm’s top position for 11 consecutive years in PlacementTracker's Market ...
PepGen price target lowered to $16 from $26 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on PepGen (PEPG) to $16 from $26 and keeps a Buy rating on the shares after the company shared the safety reports from the CONNECT1-EDO51, the Phase 2, ...